Sure, plus or minus 30% is within reason for guesstimates but the idea of 30,000 tests a day is long way higher than the daily average of 2,200 Americans who suffer strokes. Not only the variable cost would discourage the willy nilly use of the Gen 2 but in a recent presentation the company's head honcho said it takes about 9 minutes to run a test on the Gen 1. Unless there are clear indications of a stroke are the first responders going to commit 9 minutes to a suck-it-and-see test? Worth remembering that a major advantage of this machine is identifying whether they are dealing with a blood clot or a bleed to inform them what they should be doing while they are getting the person to a hospital.
Anyway, these are all just made up numbers, the important thing to note is the number of practitioners that see that the machine will add value to a life-threatening problem that affects 1 in 4 of us.
EMV Price at posting:
$1.54 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)